1. Home
  2. LCTX vs AMWL Comparison

LCTX vs AMWL Comparison

Compare LCTX & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.71

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Logo American Well Corporation

AMWL

American Well Corporation

HOLD

Current Price

$4.70

Market Cap

111.4M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCTX
AMWL
Founded
1990
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
407.7M
111.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
LCTX
AMWL
Price
$1.71
$4.70
Analyst Decision
Strong Buy
Hold
Analyst Count
4
7
Target Price
$4.25
$7.58
AVG Volume (30 Days)
1.4M
141.4K
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,816,000.00
$265,023,000.00
Revenue This Year
$5.24
N/A
Revenue Next Year
$126.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.05
4.33
52 Week Low
$0.37
$3.71
52 Week High
$2.09
$12.95

Technical Indicators

Market Signals
Indicator
LCTX
AMWL
Relative Strength Index (RSI) 46.72 61.79
Support Level $1.65 $3.92
Resistance Level $1.82 $4.86
Average True Range (ATR) 0.08 0.21
MACD 0.00 0.12
Stochastic Oscillator 48.00 85.11

Price Performance

Historical Comparison
LCTX
AMWL

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About AMWL American Well Corporation

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.

Share on Social Networks: